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Objectives. The present work was designed to test the effects of
amiodarone therapy on action potential characteristics of the
three cell types observed in human left ventricular preparations.
Background. The electrophysiologic basis for amiodarone’s
exceptional antiarrhythmic efficacy and low proarrhythmic profile
remains unclear.
Methods. We used standard microelectrode techniques to in-
vestigate the effects of chronic amiodarone therapy on transmem-
brane activity of the three predominant cellular subtypes (epicar-
dial, midmyocardial [M] and endocardial cells) spanning the
human left ventricle in hearts explanted from normal, heart
failure and amiodarone-treated heart failure patients.
Results. Tissues isolated from the ventricles of heart failure
patients receiving chronic amiodarone therapy displayed M cell
action potential duration (404 6 12 ms) significantly briefer (p <
0.05) than that recorded in tissues isolated from normal hearts
(439 6 22 ms) or from heart failure patients not treated with
amiodarone (449 6 18 ms). Endocardial cells from amiodarone-
treated heart failure patients displayed longer (p < 0.05) action
potential duration (363 6 10 ms) than endocardial cells isolated
from normal hearts (330 6 6 ms). As a consequence, the hetero-
geneity of ventricular repolarization in tissues from patients
treated with amiodarone was considerably smaller than in the two
other groups, especially at long pacing cycle lengths.
Conclusions. These findings may explain, at least in part, the
reduction of ventricular repolarization dispersion and the lower
incidence of torsade de pointes observed with chronic amiodarone
therapy as compared with other class III agents.
(J Am Coll Cardiol 1998;32:1063–7)
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Antiarrhythmic drugs can induce unexpected and sometimes
fatal reactions by either aggravating existing arrhythmias or by
producing new symptomatic arrhythmias. Torsade de pointes
(TdP) is the most common arrhythmia induced by agents with
class III actions (for recent review, see reference 1). In contrast
to most class III drugs, amiodarone has been found to be safer
in this regard and has even been used successfully in patients
who had developed TdP with other agents (2,3). The electro-
physiologic mechanism(s) responsible for the salutary effects of
amiodarone and its low arrhythmogenicity remain incom-
pletely understood (1).
The mechanisms that underlie sustained episodes of TdP
are not well understood. The role of early afterdepolarizations
(EADs)-induced triggered activity is far from clear. The devel-
opment or accentuation of dispersion of repolarization be-
tween contiguous myocardial areas leading to circus movement
of reentry as a mechanism for TdP has also been suggested (4)
and are potentiated by bradycardia (5,6). Some have suggested
that TdP may be due to triggered activity originating at two
independent foci (7). A spiral wave of reentrant excitation
migrating along the epicardial surface is another possible
mechanism (8).
Recent studies have shown that EAD activity can be
induced in a select population of cells located in the midmyo-
cardial (M) region of the canine ventricle. M cells, but not
epicardial and endocardial cells, display a marked action
potential prolongation and/or EADs in response to antiar-
rhythmic drugs such as quinidine or dl-sotalol (9). The prefer-
ential prolongation of the M cell action potential results in a
marked dispersion of ventricular recovery, creating a zone of
functional refractoriness in the midmyocardial layers of the
ventricular wall, an ideal substrate for reentry (for review, see
reference 10). We have also identified these three cell subtypes
in the human heart (11).
It has been suggested that the negligible tendency of
amiodarone to induce TdP may derive from the fact that it not
only prolongs ventricular repolarization, like other class III
agents, but also reduces dispersion of repolarization (12).
Another hypothesis could be that, unlike other class III drugs,
chronic amiodarone reduces, rather than augments, transmu-
ral dispersion of repolarization at slow rates. The present study
was designed to test this hypothesis using tissues from hearts
explanted from patients with and without chronic amiodarone
therapy.
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Methods
Patient characteristics are summarized in Table 1. Electro-
physiologic studies were performed on tissues isolated from
explanted hearts of 1) patients with normal hearts (group NH),
2) patients with heart failure not treated with amiodarone
(group HF) and 3) patients with heart failure treated with
amiodarone (group AM). Even chronically administered, the
duration of the amiodarone therapy was rather short (mean 12
weeks, range 3 to 32 weeks) without loading dose. The mean
daily dosage was 182 6 16 mg/day (range 170 to 200).
Cardioplegia was not performed. The normal hearts were
obtained from three patients with cystic fibrosis undergoing
heart-lung transplantation and from one donor whose heart
could not be matched.
After excision, the hearts were immediately immersed in
oxygenated cold Tyrode’s solution containing (in mM): NaCl,
131; NaH2PO4, 1.8; MgCl2, 0.5; CaCl2, 2.7; KCl, 4; glucose, 5.5;
mannitol, 1.1; HEPES (N-[2-hydroxyethyl] piperazine-N9-[2-
ethanesulfonic acid]), 5; pH adjusted to 7.35 with Tris ([hy-
droxymethyl] amiodarone). The hearts were transported to the
laboratory in less than 5 min. The experimental preparations
consisted of transmural slices of the left ventricular free wall
(for detail, see reference 11). They were placed in a tissue bath
and superfused with oxygenated (95% O2/5% CO2) Tyrode’s
solution (37 6 0.5°C, pH 7.35) containing (in mmol/liter):
NaCl, 131; KCl, 4; NaH2PO4, 1.8; NaHCO3, 18; CaCl2, 2.7;
MgCl2, 0.5; D-glucose, 5.5; mannitol, 1.1. The flow rate in the
tissue chamber was 12 ml/min resulting in three changes of
chamber volume per minute.
Tissues were impaled with 3 M KCl-filled glass capillary
microelectrodes. The electrodes were connected via an Ag/
AgCl interface to an amplifier having a high input impedance
and input capacity neutralization (Biologic VF-102 frame).
Output was displayed on a digital storage oscilloscope (Gould
1604, USA) coupled by a 488 IEEE-interface to a plotter
(Gould Colorwriter 6300), a chart recorder (Gould 8188) and
a modified digital audioprocessor (Sony PCM-501ES, Japan)
coupled to a videotape recorder (JVC HR-D755S). The tissue
chamber was connected to ground through a salt bridge (3 M
KCl) and an Ag/AgCl junction.
Electrophysiologic studies were performed after 2 h of
recovery, during which time tissues were paced at a cycle
length of 1 s via Teflon-coated bipolar silver wire electrodes.
Stimulus pulse width was 1.5 ms and amplitude was twice
diastolic threshold. During the experiments, the action poten-
tials (AP) were recorded at pacing cycle lengths (PCL) of 1, 2,
3, 4, 5, 6 and 10 s (always in this sequence). Action potential
characteristics were measured at steady state for each PCL.
We measured the maximal diastolic potential, the amplitude of
phase 0, the maximal rate of rise of phase 0 (Vmax) and the AP
duration at 90% of full repolarization (APD90). Only data
from impalements that were maintained throughout the course
of the experiment were analyzed.
JT interval instead of QT interval was used to assess
ventricular repolarization duration on standard electrocardio-
gram (ECG). This limits the bias linked to the varying QRS
duration. The JT interval duration was determined from the
end of the QRS complex to the end of the T wave. The end of
the T wave was defined as the intersection of the isoelectric
line with the tangent to the maximal down slope of the T wave
(13). Considering the large range of RR intervals in our study
(Table 1), we decided to correct the JT interval using the
Fridericia formula (JTc 5 JT/(RR)1/3). The latter formula has
been shown to limit the deficiencies of the Bazett formula
(JTc 5 JT/(RR)1/2) when correcting QT interval duration for
a wide range of heart rate (14,15). We used the mean of five
consecutive JT intervals on lead V2 from a standard ECG.
Data were expressed as mean 6 SE. Statistical analysis was
performed using nonparametric Wilcoxon or U–Mann–
Whitney tests, for paired or unpaired data, respectively. The
Abbreviations and Acronyms
AM 5 group of patients treated with amiodarone
APD 5 action potential duration
EAD 5 early afterdepolarization
ECG 5 electrocardiogram
HF 5 group of patients with heart failure
NH 5 group of patients with normal heart
PCL 5 pacing cycle length
TdP 5 torsade de pointes
Vmax 5 maximal rate of rise of phase 0 of the action potential
Table 1. Patient Characteristics
N
(sex)
Age
(yr) Disease RR (ms) JT (ms) JTc (ms)
Group AM 5 34–60 1 DC 554 6 63 228 6 24 278 6 22
(1 F, 4 M) 3 CI (n 5 5)
1 IC
Group HF 2 55–58 2 DC 726 6 50 249 6 2 277 6 8
(2 M) (n 5 2)
Group NH 4 14–46 3 CF 809 6 277 295 6 25 321 6 19
(2 F, 2 M) 1 normal donor (n 5 3)
CF 5 cystic fibrosis; CI 5 cardiac infarct; DC 5 dilated cardiomyopathy; F 5 female; group AM 5 patients with heart failure treated with amiodarone; group HF 5
patients with heart failure not treated with amiodarone; group NH 5 patients with normal heart; IC 5 ischemic cardiomyopathy; M 5 male; N 5 number of patients
for the study; n 5 number of ECG available.
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effects of PCL on APD90 were determined by two-way analysis
of variance. A value of p , 0.05 was considered significant.
Results
Action potential configuration. Table 2 summarizes the AP
characteristics of the three cell types observed in human left
ventricular preparations paced at a cycle length of 1 s. These
data are illustrated in Figure 1. There was no significant
difference in resting potential and amplitude of phase 0
between the cellular subtypes and from one group to another.
Vmax was significantly higher in M cells than in epicardial and
endocardial cells for all groups. However, Vmax was decreased
in all cellular subtypes of ventricular preparations from the
AM group relative to the NH and HF groups. In all cases,
APD90 was significantly higher in M cells than in other cell
types. However, APD90 of M cells was significantly reduced in
group AM compared to groups HF (p , 0.05) and NH (p ,
0.05), whereas APD90 of epicardial cells was unchanged and
APD90 of endocardial cells was greater in the HF (p , 0.05)
and AM (p , 0.05) groups than in the NH group.
Rate-dependence of action potential duration. Figure 2
shows APD90-rate relations of the three cellular subtypes in
the three groups studied. Treatment with amiodarone had
little effect on epicardial and endocardial cells. However, after
treatment with amiodarone, APD90 of M cells was significantly
reduced (p , 0.05), especially at long PCL, and the slope of
their APD90-rate relation was no longer steeper than that of
other cellular subtypes: the typical response of M cells to
bradycardia, that is, the large increase of their APD, was lost
(see also Fig. 1).
Discussion
Amiodarone is a unique antiarrhythmic compound with
poorly understood electrophysiologic effects (16). It acts pri-
marily by prolonging ventricular repolarization (16,17), and for
this reason has been defined as a class III antiarrhythmic agent,
but its electrophysiologic effects fit all four classes (16). Ami-
odarone differs from other class III agents in reducing QT
dispersion (12). Besides its remarkable antiarrhythmic and
antifibrillatory efficacy, this compound has a low proclivity to
induce proarrhythmia despite its significant class I properties.
The precise mechanism for this low incidence of amiodarone-
associated proarrhythmia remains speculative, but differential
effects on APD of varying lengths in ventricular myocardium
could be involved in this unexplained paradox.
Amiodarone and transmural heterogeneity. Up to now the
effects of amiodarone treatment on M cells in the human heart
were not known. This study suggests that chronic treatment
with amiodarone reduces the transmural dispersion of ventric-
ular repolarization in human heart. This comes from a differ-
Figure 1. Action potentials recorded under steady-state conditions at
PCLs of 1 s (a) and 10 s (b) from epicardial (EPI), deep subepicardial
(M cell) and endocardial cells (ENDO) regions of transmural prepa-
rations isolated from the left ventricles of AM, NH and HF groups.
Table 2. Characteristics of Action Potentials Recorded at a Pacing Cycle Length of 1 s in
Epicardial, M Region and Endocardial Cells
Epicardium M region Endocardium
MDP (mV) Group AM 290 6 1 288 6 1 287 6 1
Group HF 285 6 1 285 6 1 287 6 3
Group NH 286 6 1 286 6 4 287 6 1
Ph 0 amp (mV) Group AM 107 6 4 110 6 2# 104 6 2
Group HF 98 6 2 108 6 4§ 105 6 4
Group NH 104 6 2 105 6 3 105 6 2
Vmax (V/sec) Group AM 139 6 27 162 6 11* 126 6 12
Group HF 171 6 11 320 6 38* 180 6 45
Group NH 228 6 11 326 6 16* 234 6 28
APD90 (msec) Group AM 356 6 3 404 6 12*¶ 363 6 10
Group HF 358 6 4 449 6 18* 382 6 18
Group NH 351 6 14 439 6 22* 330 6 16**
*p , 0.05 vs. epicardium and endocardium; #p , 0.05 vs. endocardium; §p , 0.05 vs. epicardium; **p , 0.05 vs.
groups HF and AM; ¶p , 0.05 vs. groups HF and NH. APD90 5 action potential duration at 90% of full repolarization;
group AM 5 patients with heart failure treated with amiodarone; group HF 5 patients with heart failure not treated with
amiodarone; group NH 5 patients with normal heart; MDP 5 maximum diastolic potential; Ph 0 amp 5 phase 0
amplitude; Vmax 5 maximum upstroke velocity of phase 0 of the action potential.
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ential effect of amiodarone on repolarization of the different
cellular subtypes. In the AM group, the heterogeneity of
ventricular repolarization was considerably smaller than in the
two other groups, especially at long PCLs. Comparable results
were found by Sicouri et al. (18) in dogs chronically treated
with amiodarone. These authors showed that APD in M cells
was reduced by amiodarone, especially at long PCLs, while
APD in endocardium was prolonged. These results, that is, an
important decrease in transmural dispersion of repolarization,
are typically those obtained in our study. They also showed that
the epicardial AP was the least modified by amiodarone, which
is what we also observed.
It is of interest that previous studies showing that chronic
amiodarone prolongs the AP of ventricular myocardium were
performed on endocardium isolated from normal animals. A
differential effect of amiodarone has also been observed by
Yabek et al. (19), who showed that superfusion with amioda-
rone reduced APD of Purkinje fibers from nontreated dogs,
but prolonged APD of the surrounding myocardium.
M cells have electrophysiologic properties similar to those
of Purkinje cells: their APs are longer than that of other
cellular subtypes and they are markedly prolonged by brady-
cardia. After treatment with amiodarone, the APD of M cells
no longer increases dramatically with PCL. It was shown that
M cells, because of their typical response to bradycardia, are
more sensitive than other myocardial cells to drugs that
prolong repolarization and induce EADs and triggered activity
(9). This double effect of amiodarone, that is, to decrease
transmural heterogeneity of ventricular repolarization and to
suppress M cells sensitivity to bradycardia, may explain its
clinical properties. Indeed, the homogenization of ventricular
repolarization (Fig. 2) could explain, at least in part, why
amiodarone differs from other class III agents such as sotalol
or sematilide.
The absence of steeper APD-rate relationship of M cells
could lead to a corresponding reduction in the possibility of
pharmacologically induced EADs and reentrant mechanisms
and may account for the lower incidence of TdP, compared to
that after dl-sotalol or other class III which tend to increase
APD in M cells to a greater extent than in epicardial and
endocardial cells (10). As already noted, it is well known that
EADs that give rise to TdP appear to arise in Purkinje network
and M cells with transmission to ventricular muscle. Further-
more, it was reported that amiodarone may prove to be a
suitable therapeutic option for TdP in patients with drug-
induced TdP (2,3).
Another finding of this study is that heart failure does not
seem to prolong repolarization of epicardial and M cells. Only
endocardial APs were significantly prolonged compared to
normal hearts. This prolongation of endocardial APs has
already been observed in other studies (20).
Amiodarone and JTc interval. Amiodarone is well known
to prolong QT interval (21). However, various responses in
QTc prolongation depend on both the duration of the treat-
ment and the dose. Pollack et al. (22) found that 70% of the
QTc interval lengthening occurred between 9 and 12 months
after treatment initiation. Besides, previous reports of patients
receiving a mean dose of 380 mg/day showed only an 8%
increase in QTc interval (23,24), whereas patients receiving
600 to 1,200 mg/day have shown a 23% increase (25). In our
study, amiodarone did not induce a prolongation of the JTc
interval, in agreement with our in vitro results. We believe that
this effect was due to both a rather short duration of treatment
and a small dose of amiodarone. These results are comparable
Figure 2. Effects of PCL on APD90 in NH (16 preparations), HF (6
preparations) and AM (11 preparations) groups. Epicardial, endocar-
dial and M cells are depicted by circles, squares and triangles,
respectively.
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to those obtained by Sicouri et al. (18) in dogs. Thus, we can
speculate that amiodarone treatment induces in a first time a
decrease of the transmural heterogeneity and in a second time
a prolongation of ventricular repolarization.
Limitations of the study. Aside from the obvious limita-
tions inherent in studying tissues isolated from their native
milieu, this study has the additional limitation of not being able
to compare the effects of chronic amiodarone in normal hearts.
The data, from which the actions of amiodarone are deduced,
derive from a heterogeneous mixture of diseased hearts.
Another limitation comes from the small number of patients
with heart failure. This comes from the fact that amiodarone,
or other drugs having major effects on repolarization, is
frequently prescribed to patients with severe heart failure.
These limitations notwithstanding, the results are sufficiently
compelling to warrant further investigation into the problem.
Conclusion. In summary, these data indicate for the first
time that an important aspect of the antiarrhythmic action of
amiodarone in humans may be its differential electrophysi-
ologic effects on the three cellular subtypes, leading to more
homogeneous repolarization across the ventricular wall. This
may explain at least in part the reduced incidence of TdP and
ventricular fibrillation with amiodarone compared to other
class III antiarrhythmic drugs. Finally, we should keep in mind
that the electrophysiologic properties of amiodarone are prob-
ably more complex and multifactorial.
The authors contributed to this study the following way: Emmanuel Drouin, the
in vitro experiments on the human hearts; Gilles Lande, the analysis of the ECGs
and discussion; and Flavien Charpentier, the supervision of the work and
preparation of the manuscript.
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